FDA's Peter Maxim
This article was originally published in The Gray Sheet
Executive SummaryChief of the Division of Clinical Laboratory Devices' Immunology/Molecular Diagnostics Branch is remembered at funeral services March 3 following his sudden passing Feb. 27 from a heart attack. Maxim served as executive secretary of the FDA device center's Molecular and Clinical Genetics Panel and received FDA's Outstanding Achievement Award in 1999
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.